keyword
MENU ▼
Read by QxMD icon Read
search

breast chemotherapy

keyword
https://www.readbyqxmd.com/read/29679201/utilization-of-the-21-gene-recurrence-score-in-a-diverse-breast-cancer-patient-population-development-of-a-clinicopathologic-model-to-predict-high-risk-scores-and-response-to-neoadjuvant-chemotherapy
#1
Ko Un Park, Yalei Chen, Dhananjay Chitale, Sarah Choi, Haythem Ali, S David Nathanson, Jessica Bensenhaver, Erica Proctor, Lindsay Petersen, Randa Loutfi, Alyson Simonds, Marcia Kuklinski, Thomas Doyle, Vrushali Dabak, Kim Cole, Melissa Davis, Lisa Newman
INTRODUCTION: The 21-gene expression profile [Oncotype DX Recurrence Score (RS)] stratifies benefit from adjuvant chemotherapy in hormone receptor (HR)-positive, HER2/neu-negative, node-negative breast cancer. It is not routinely applied to predict neoadjuvant chemotherapy (NACT) response; data in diverse patient populations also are limited. We developed a statistical model based on standard clinicopathologic features to identify high-risk cases (RS > 30) and then evaluated ability of predicted high RS to predict for NACT downstaging...
April 20, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29678980/health-related-quality-of-life-in-asian-patients-with-breast-cancer-a-systematic-review
#2
Peh Joo Ho, Sofie A M Gernaat, Mikael Hartman, Helena M Verkooijen
OBJECTIVE: To summarise the evidence on determinants of health-related quality of life (HRQL) in Asian patients with breast cancer. DESIGN: Systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations and registered with PROSPERO (CRD42015032468). METHODS: According to the PRISMA guidelines, databases of MEDLINE (PubMed), Embase and PsycINFO were systematically searched using the following terms and synonyms: breast cancer, quality of life and Asia...
April 20, 2018: BMJ Open
https://www.readbyqxmd.com/read/29678846/the-predictive-significance-of-metastasis-associated-in-colon-cancer-1-macc1-in-primary-breast-cancer
#3
Jasminka Prguda-Mujic, Karin Milde-Langosch, Volkmar Mueller, Mirza Suljagic, Jozo Coric, Daria Ler
BACKGROUND: Metastasis-Associated in Colon Cancer-1(MACC1) was first identified as a transcriptional activator of the HGF/MET pathway. Deregulation of HGF/MET signaling is reported as a prognostic marker for tumorigenesis, early stage invasion, and metastasis which is associated with poor clinical outcome in breast cancer patients. The aim of the present study was to further investigate the prognostic or predictive value of MACC1 expression in breast cancer. MATERIALS AND METHODS: We analyzed the MACC1 expression in 105 primary breast cancer samples by Western-Blot analysis and immunohistochemistry...
March 2018: Annals of Clinical and Laboratory Science
https://www.readbyqxmd.com/read/29678178/status-of-lipid-and-lipoprotein-in-female-breast-cancer-patients-at-initial-diagnosis-and-during-chemotherapy
#4
Xin Li, Zi-Li Liu, Yu-Tuan Wu, He Wu, Wei Dai, Bilal Arshad, Zhou Xu, Hao Li, Kai-Nan Wu, Ling-Quan Kong
BACKGROUND: The lipid profile status among breast cancer patients at initial diagnosis and during chemotherapy remain controversial. The aim of this study is to study the status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. METHODS: We conducted a retrospective cohort study of the status of the lipid and lipoprotein in 1054 primarily diagnosed breast cancer patients and 2483 normal controls with age stratification, from July 2015 to October 2016...
April 20, 2018: Lipids in Health and Disease
https://www.readbyqxmd.com/read/29678165/retrospective-analysis-of-the-impact-of-anthracycline-dose-reduction-and-chemotherapy-delays-on-the-outcomes-of-early-breast-cancer-molecular-subtypes
#5
Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite, Elona Juozaityte
BACKGROUND: The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. METHODS: Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up...
April 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29677569/validation-of-the-ajcc-8th-prognostic-system-for-breast-cancer-in-an-asian-healthcare-setting
#6
R X Wong, F Y Wong, John Lim, W X Lian, Y S Yap
AIMS: We aim to validate the AJCC 8th edition prognostic staging system for breast cancer in an Asian setting. METHODS: Clinico-pathologic information and cancer-specific survival (CSS) outcomes of 6287 stage I to III patients with invasive breast cancer who underwent upfront surgery at SingHealth institutions in Singapore from 2006 to 2014 were analyzed. Survival distributions for the different staging systems were estimated by the Kaplan-Meier method and compared using the log-rank tests...
April 17, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29675680/a-randomized-double-blind-phase-2-study-of-ruxolitinib-or-placebo-in-combination-with-capecitabine-in-patients-with-advanced-her2-negative-breast-cancer-and-elevated-c-reactive-protein-a-marker-of-systemic-inflammation
#7
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S Rugo
PURPOSE: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1). METHODS: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine...
April 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29674800/olanzapine-versus-aprepitant-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients-receiving-doxorubicin-cyclophosphamide-regimen-a-prospective-nonrandomized-open-label-study
#8
G Shivaprakash, Karthik S Udupa, V Sarayu, Joseph Thomas, Vishal Gupta, L C Pallavi, Sudhakar Pemminati
OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen. PATIENTS AND METHODS: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology...
November 2017: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/29674477/blockade-of-myeloid-derived-suppressor-cell-expansion-with-all-trans-retinoic-acid-increases-the-efficacy-of-anti-angiogenic-therapy
#9
Raimund Bauer, Florian Udonta, Mark Wroblewski, Isabel Ben-Batalla, Ines Miranda Santos, Federico Taverna, Meike Kuhlencord, Victoria Gensch, Sarina Päsler, Stefan Vinckier, Johanna M Brandner, Klaus Pantel, Carsten Bokemeyer, Thomas Vogl, Johannes Roth, Peter Carmeliet, Sonja Loges
Intrinsic and adaptive resistance hamper the success of anti-angiogenic therapies (AAT), especially in breast cancer where this treatment modality has proven largely ineffective. Therefore, novel strategies to improve the efficacy of AAT are warranted. Solid tumors such as breast cancer are characterized by a high infiltration of myeloid-derived suppressor cells (MDSC) which are key drivers of resistance to AAT. Therefore, we hypothesized that all-trans retinoic acid (ATRA), which induces differentiation of MDSC into mature cells, could improve the therapeutic effect of AAT...
April 19, 2018: Cancer Research
https://www.readbyqxmd.com/read/29674173/precision-medicine-with-imprecise-therapy-computational-modeling-for-chemotherapy-in-breast-cancer
#10
REVIEW
Matthew T McKenna, Jared A Weis, Amy Brock, Vito Quaranta, Thomas E Yankeelov
Medical oncology is in need of a mathematical modeling toolkit that can leverage clinically-available measurements to optimize treatment selection and schedules for patients. Just as the therapeutic choice has been optimized to match tumor genetics, the delivery of those therapeutics should be optimized based on patient-specific pharmacokinetic/pharmacodynamic properties. Under the current approach to treatment response planning and assessment, there does not exist an efficient method to consolidate biomarker changes into a holistic understanding of treatment response...
April 16, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29674005/breast-cancer-cutaneous-metastases-mimicking-papilloma-cutis-lymphostatica-biopsy-to-avoid-pitfalls
#11
Giuseppe Giudice, Michelangelo Vestita, Fabio Robusto, Paolo Annoscia, Francesco Ciancio, Eleonora Nacchiero
INTRODUCTION: Secondary lymphedema is the most frequent long-term complication of axillary lymphadenectomy. It can result in complication as erysipelas, warts, Papilloma Cutis Lymphostatica (PCL), or angiosarcomas. Moreover, in women affected by breast cancer an accurate differential diagnosis among these conditions or complication related to radiation dermatitis or cutaneous metastasis is essential. PRESENTATION OF CASE: We report the case of a 60-year-old postmenopausal Caucasian woman affected by secondary lymphedema following complete mastectomy for breast cancer...
April 10, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29673642/hyperthermia-mediated-drug-delivery-induces-biological-effects-at-the-tumor-and-molecular-levels-that-improve-cisplatin-efficacy-in-triple-negative-breast-cancer
#12
Michael Dunne, Yannan N Dou, Danielle M Drake, Tara Spence, Sávio M L Gontijo, Peter G Wells, Christine Allen
Triple negative breast cancer is an aggressive disease that accounts for at least 15% of breast cancer diagnoses, and a disproportionately high percentage of breast cancer related morbidity. Intensive research efforts are focused on the development of more efficacious treatments for this disease, for which therapeutic options remain limited. The high incidence of mutations in key DNA repair pathways in triple negative breast cancer results in increased sensitivity to DNA damaging agents, such as platinum-based chemotherapies...
April 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29673111/comparison-of-epidemiological-features-clinicopathological-features-and-treatments-between-premenopausal-and-postmenopausal-female-breast-cancer-patients-in-western-china-a-retrospective-multicenter-study-of-15-389-female-patients
#13
REVIEW
Fan Feng, Yuxian Wei, Ke Zheng, Yujing Li, Lu Zhang, Tielin Wang, Yanli Zhang, Hongyuan Li, Guosheng Ren, Fan Li
Premenopausal and postmenopausal breast cancers are considered different types. Thus, this study aimed to explore differences in risk factors, epidemiological features, clinicopathological features, and treatment modes of premenopausal breast cancer compared to postmenopausal patients in western China. This was a hospital-based, retrospective, multicenter epidemiological study of patients with breast cancer. Using the Western China Clinical Cooperation Group database, we obtained the records of 15,389 female breast cancers between January 2010 and April 2017...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29671222/prognostic-value-of-ki-67-according-to-age-in-patients-with-triple-negative-breast-cancer
#14
V Zenzola, M A Cabezas-Quintario, M Arguelles, E Pérez-Fernández, Y Izarzugaza, A Correa, J García-Foncillas
PURPOSE: The prognostic value of Ki-67 in triple-negative breast cancer (TNBC) is yet unclear because the cut-off points employed differ widely and its predictive effect may vary according to age. The purpose of this study was to analyze the role of Ki-67 among patients with TNBC, and determine the optimal Ki-67 cut-off point to demonstrate its prognostic relevance associated with patient age and treatment strategy. METHODS/PATIENTS: 201 consecutive patients treated for primary TNBC from 1999 to 2014 were analyzed...
April 18, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29671138/nipple-sparing-mastectomy-is-not-associated-with-a-delay-of-adjuvant-treatment
#15
Emily L Albright, Mary C Schroeder, Kendra Foster, Sonia L Sugg, Lillian M Erdahl, Ronald J Weigel, Ingrid M Lizarraga
BACKGROUND: High-volume single-institution studies support the oncologic safety of nipple sparing mastectomy (NSM). Concerns remain regarding the increased potential for complications, recurrence, and delays to subsequent adjuvant therapy. A national database was used to examine treatment and outcomes for NSM patients. METHODS: Women undergoing unilateral NSM or skin sparing mastectomy (SSM) for stage 0-4 breast cancer from 2004 to 2013 were identified from the National Cancer Database...
April 18, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29671072/reversion-of-multidrug-resistance-by-co-encapsulation-of-doxorubicin-and-metformin-in-poly-lactide-co-glycolide-d-%C3%AE-tocopheryl-polyethylene-glycol-1000-succinate-nanoparticles
#16
Vahid Shafiei-Irannejad, Nasser Samadi, Roya Salehi, Bahman Yousefi, Mahdi Rahimi, Abolfazl Akbarzadeh, Nosratollah Zarghami
PURPOSE: P-glycoprotein (P-gp) mediated multidrug resistance (MDR) has been recognized as the main obstacle against successful cancer treatment. To address this problem, co-encapsulated doxorubicin (DOX) and metformin (Met) in a biodegradable polymer composed of poly(lactide-co-glycolide) (PLGA) and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared. We reported in our previous study that Met inhibits P-gp in DOX resistant breast cancer (MCF-7/DOX) cells. TPGS is a bioactive compound which has also been shown to inhibit P-gp, further to its pharmaceutical advantages...
April 18, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29670925/pseudocirrhosis-in-a-patient-with-new-onset-dysphagia-and-history-of-ovarian-carcinoma
#17
Andrew Zanazanian, Amir Kalani, James H Tabibian
Pseudocirrhosis is an infrequently reported clinico-radiologic complication that primarily occurs in a subset of patients with a history of breast carcinoma metastatic to the liver that has been treated with systemic chemotherapy, particularly capecitabine, gemcitabine, trastuzumab, and/or paclitaxel. Even less common are cases of pseudocirrhosis secondary to other (i.e., non-breast) carcinomas. We describe a 43-year-old woman with a history of metastatic ovarian carcinoma treated several years prior with systemic chemotherapy who presented with progressive dysphagia and was found to have gastroesophageal junction adenocarcinoma and, incidentally, pseudocirrhosis...
2018: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29670855/current-therapies-for-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer-patients
#18
REVIEW
Alexey A Larionov
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29670372/postmastectomy-radiotherapy-reduces-locoregional-and-disease-recurrence-in-patients-with-stage-ii-iii-triple-negative-breast-cancer-treated-with-neoadjuvant-chemotherapy-and-mastectomy
#19
Xingxing Chen, Fan Xia, Jurui Luo, Jinli Ma, Zhaozhi Yang, Li Zhang, Yan Feng, Zhimin Shao, Xiaoli Yu, Xiaomao Guo
Background: This study investigated the effect of postmastectomy radiotherapy (PMRT) in patients with stage II-III triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NAC) and modified radical mastectomy (MRM). Patients and methods: A total of 104 women with stage II-III TNBC who received NAC and MRM at our institution between January 2000 and July 2007 were identified. Patients were divided into 2 groups (PMRT and non-PMRT) for statistical analysis...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29669584/mri-based-response-patterns-during-neoadjuvant-chemotherapy-can-predict-pathological-complete-response-in-patients-with-breast-cancer
#20
Briete Goorts, Kelly M A Dreuning, Janneke B Houwers, Loes F S Kooreman, Evert-Jan G Boerma, Ritse M Mann, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included...
April 18, 2018: Breast Cancer Research: BCR
keyword
keyword
82103
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"